Buchbinder, Aby

Randomized phase 2 study of pegylated SN‐38 (EZN‐2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer

Garrett, C. R., Bekaii‐Saab, T. S., Ryan, T., Fisher, G. A., Clive, S., Kavan, P., Shacham‐Shmueli, E., Buchbinder, A., & Goldberg, R. M. (2013) · Cancer

Colorectal Cancer Treatments and StudiesCancer therapeutics and mechanisms

Cited by 62

Safety, pharmacokinetics, and activity of EZN‐2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies

Kurzrock, R., Goel, S., Wheler, J., Hong, D., Fu, S., Rezai, K., Morgan‐Linnell, S. K., Urien, S., Mani, S., Chaudhary, I., et al. (2012) · Cancer

Cancer therapeutics and mechanismsPharmacogenetics and Drug Metabolism

Cited by 50

Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors: Phase 1 Trial of EZN2208

Norris, R. E., Shusterman, S., Gore, L., Muscal, J. A., Macy, M. E., Fox, E., Berkowitz, N., Buchbinder, A., & Bagatell, R. (2014) · Pediatric Blood & Cancer

Cancer therapeutics and mechanismsPharmaceutical studies and practices

Cited by 38

EZN-2968, a novel hypoxia-inducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) antagonist: Results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies

Patnaik, A., Chiorean, E. G., Tolcher, A., Papadopoulos, K., Beeram, M., Kee, D., Waddell, M., Gilles, E., & Buchbinder, A. (2009) · Journal of Clinical Oncology

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 26

Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC).

Osborne, C. R. C., O'Shaughnessy, J., Holmes, F. A., Kim, H. S., Kocs, D. M., Steinberg, M. S., Richards, P. D., Vukelja, S. J., Berkowitz, N. C., & Buchbinder, A. (2012) · Journal of Clinical Oncology

Cancer Treatment and PharmacologyCancer therapeutics and mechanisms

Cited by 10

Abstract LB-407: Down-modulation of mRNA by EZN-2968, an hypoxia-inducible factor-1α (HIF-1α) mRNA antagonist, administered in adult patients with advanced solid tumors

Cohen, R. B., Olszanski, A., Figueroa, J., Hurwitz, H., Lokiec, F. M., Rezaï, K., Berkowitz, N., & Buchbinder, A. (2011) · Cancer Research

Cancer, Hypoxia, and MetabolismRNA Interference and Gene Delivery

Cited by 1